Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation
The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome p...
Gespeichert in:
Veröffentlicht in: | Cancer biotherapy & radiopharmaceuticals 2011-10, Vol.26 (5), p.623 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 5 |
container_start_page | 623 |
container_title | Cancer biotherapy & radiopharmaceuticals |
container_volume | 26 |
creator | Teksoz, Serap Ichedef, Cigdem Acar Ozyuncu, Seniha Muftuler, Fazilet Zumrut Biber Unak, Perihan Medine, Ilker Emin Ertay, Turkan Eren, Mine Sencan |
description | The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium ([sup.99m]Tc) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of [sup.99m]Tc-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. [sup.99m]Tc-D-PA-Glu exhibited more accumulation on PC-3 cells versus [sup.99m]Tc-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of [sup.99m]TcD-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. [sup.99m]Tc-D-PA-Glu and [sup.99m]Tc-D-PA have exhibited different biodistribution results. Key words: glucuronidation, PC-3 cell line, penicillamine, radiolabeling, scintigraphy, [sup.99m]Tc |
doi_str_mv | 10.1089/cbr.2010.0854 |
format | Article |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A270462798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A270462798</galeid><sourcerecordid>A270462798</sourcerecordid><originalsourceid>FETCH-LOGICAL-g137t-9fb8d93b04bec575ee1c000d92c96e91c96d767be977a3bb465b223c8d42de183</originalsourceid><addsrcrecordid>eNptjs1LxDAQxXNQcF09ei943axJ-pHG27J-woKX9eBpyce0jqSJNG3B_97KevAgA294P94Mj5Arztac1erGmn4t2OxYXRYnZDHDgipZl2fkPKUPxljFKrkgb3tL7-gnBLTove4wAG39aMc-BnRwm6WvMLxDwrTKeu0wem3AY2hXGYZswqGPmQ7uaKaYwaT9qAeM4YKcNtonuPzdS_L6cL_fPtHdy-PzdrOjLc_lQFVjaqdywwoDtpQlALdzO6eEVRUoPquTlTSgpNS5MUVVGiFyW7tCOOB1viTXx7-t9nDA0MSh17bDZA8bIVlRCal-Uut_UvM46NDGAA3O_M_BN0ACYmo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation</title><source>Alma/SFX Local Collection</source><creator>Teksoz, Serap ; Ichedef, Cigdem Acar ; Ozyuncu, Seniha ; Muftuler, Fazilet Zumrut Biber ; Unak, Perihan ; Medine, Ilker Emin ; Ertay, Turkan ; Eren, Mine Sencan</creator><creatorcontrib>Teksoz, Serap ; Ichedef, Cigdem Acar ; Ozyuncu, Seniha ; Muftuler, Fazilet Zumrut Biber ; Unak, Perihan ; Medine, Ilker Emin ; Ertay, Turkan ; Eren, Mine Sencan</creatorcontrib><description>The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium ([sup.99m]Tc) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of [sup.99m]Tc-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. [sup.99m]Tc-D-PA-Glu exhibited more accumulation on PC-3 cells versus [sup.99m]Tc-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of [sup.99m]TcD-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. [sup.99m]Tc-D-PA-Glu and [sup.99m]Tc-D-PA have exhibited different biodistribution results. Key words: glucuronidation, PC-3 cell line, penicillamine, radiolabeling, scintigraphy, [sup.99m]Tc</description><identifier>ISSN: 1084-9785</identifier><identifier>DOI: 10.1089/cbr.2010.0854</identifier><language>eng</language><publisher>Mary Ann Liebert, Inc</publisher><subject>Care and treatment ; Diagnosis ; Health aspects ; Liquid chromatography ; Penicillamine ; Prostate cancer</subject><ispartof>Cancer biotherapy & radiopharmaceuticals, 2011-10, Vol.26 (5), p.623</ispartof><rights>COPYRIGHT 2011 Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Teksoz, Serap</creatorcontrib><creatorcontrib>Ichedef, Cigdem Acar</creatorcontrib><creatorcontrib>Ozyuncu, Seniha</creatorcontrib><creatorcontrib>Muftuler, Fazilet Zumrut Biber</creatorcontrib><creatorcontrib>Unak, Perihan</creatorcontrib><creatorcontrib>Medine, Ilker Emin</creatorcontrib><creatorcontrib>Ertay, Turkan</creatorcontrib><creatorcontrib>Eren, Mine Sencan</creatorcontrib><title>Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation</title><title>Cancer biotherapy & radiopharmaceuticals</title><description>The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium ([sup.99m]Tc) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of [sup.99m]Tc-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. [sup.99m]Tc-D-PA-Glu exhibited more accumulation on PC-3 cells versus [sup.99m]Tc-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of [sup.99m]TcD-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. [sup.99m]Tc-D-PA-Glu and [sup.99m]Tc-D-PA have exhibited different biodistribution results. Key words: glucuronidation, PC-3 cell line, penicillamine, radiolabeling, scintigraphy, [sup.99m]Tc</description><subject>Care and treatment</subject><subject>Diagnosis</subject><subject>Health aspects</subject><subject>Liquid chromatography</subject><subject>Penicillamine</subject><subject>Prostate cancer</subject><issn>1084-9785</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptjs1LxDAQxXNQcF09ei943axJ-pHG27J-woKX9eBpyce0jqSJNG3B_97KevAgA294P94Mj5Arztac1erGmn4t2OxYXRYnZDHDgipZl2fkPKUPxljFKrkgb3tL7-gnBLTove4wAG39aMc-BnRwm6WvMLxDwrTKeu0wem3AY2hXGYZswqGPmQ7uaKaYwaT9qAeM4YKcNtonuPzdS_L6cL_fPtHdy-PzdrOjLc_lQFVjaqdywwoDtpQlALdzO6eEVRUoPquTlTSgpNS5MUVVGiFyW7tCOOB1viTXx7-t9nDA0MSh17bDZA8bIVlRCal-Uut_UvM46NDGAA3O_M_BN0ACYmo</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Teksoz, Serap</creator><creator>Ichedef, Cigdem Acar</creator><creator>Ozyuncu, Seniha</creator><creator>Muftuler, Fazilet Zumrut Biber</creator><creator>Unak, Perihan</creator><creator>Medine, Ilker Emin</creator><creator>Ertay, Turkan</creator><creator>Eren, Mine Sencan</creator><general>Mary Ann Liebert, Inc</general><scope/></search><sort><creationdate>20111001</creationdate><title>Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation</title><author>Teksoz, Serap ; Ichedef, Cigdem Acar ; Ozyuncu, Seniha ; Muftuler, Fazilet Zumrut Biber ; Unak, Perihan ; Medine, Ilker Emin ; Ertay, Turkan ; Eren, Mine Sencan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g137t-9fb8d93b04bec575ee1c000d92c96e91c96d767be977a3bb465b223c8d42de183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Care and treatment</topic><topic>Diagnosis</topic><topic>Health aspects</topic><topic>Liquid chromatography</topic><topic>Penicillamine</topic><topic>Prostate cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Teksoz, Serap</creatorcontrib><creatorcontrib>Ichedef, Cigdem Acar</creatorcontrib><creatorcontrib>Ozyuncu, Seniha</creatorcontrib><creatorcontrib>Muftuler, Fazilet Zumrut Biber</creatorcontrib><creatorcontrib>Unak, Perihan</creatorcontrib><creatorcontrib>Medine, Ilker Emin</creatorcontrib><creatorcontrib>Ertay, Turkan</creatorcontrib><creatorcontrib>Eren, Mine Sencan</creatorcontrib><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Teksoz, Serap</au><au>Ichedef, Cigdem Acar</au><au>Ozyuncu, Seniha</au><au>Muftuler, Fazilet Zumrut Biber</au><au>Unak, Perihan</au><au>Medine, Ilker Emin</au><au>Ertay, Turkan</au><au>Eren, Mine Sencan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation</atitle><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle><date>2011-10-01</date><risdate>2011</risdate><volume>26</volume><issue>5</issue><spage>623</spage><pages>623-</pages><issn>1084-9785</issn><abstract>The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium ([sup.99m]Tc) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of [sup.99m]Tc-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. [sup.99m]Tc-D-PA-Glu exhibited more accumulation on PC-3 cells versus [sup.99m]Tc-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of [sup.99m]TcD-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. [sup.99m]Tc-D-PA-Glu and [sup.99m]Tc-D-PA have exhibited different biodistribution results. Key words: glucuronidation, PC-3 cell line, penicillamine, radiolabeling, scintigraphy, [sup.99m]Tc</abstract><pub>Mary Ann Liebert, Inc</pub><doi>10.1089/cbr.2010.0854</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1084-9785 |
ispartof | Cancer biotherapy & radiopharmaceuticals, 2011-10, Vol.26 (5), p.623 |
issn | 1084-9785 |
language | eng |
recordid | cdi_gale_infotracmisc_A270462798 |
source | Alma/SFX Local Collection |
subjects | Care and treatment Diagnosis Health aspects Liquid chromatography Penicillamine Prostate cancer |
title | Tc-D-penicillamine-glucuronide: synthesis, radiolabeling, in vitro and in vivo evaluation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T16%3A56%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tc-D-penicillamine-glucuronide:%20synthesis,%20radiolabeling,%20in%20vitro%20and%20in%20vivo%20evaluation&rft.jtitle=Cancer%20biotherapy%20&%20radiopharmaceuticals&rft.au=Teksoz,%20Serap&rft.date=2011-10-01&rft.volume=26&rft.issue=5&rft.spage=623&rft.pages=623-&rft.issn=1084-9785&rft_id=info:doi/10.1089/cbr.2010.0854&rft_dat=%3Cgale%3EA270462798%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A270462798&rfr_iscdi=true |